Hostname: page-component-586b7cd67f-rdxmf Total loading time: 0 Render date: 2024-11-29T04:01:38.211Z Has data issue: false hasContentIssue false
  • English
  • Français

The report of the joint WPA/CINP workgroup on the use and usefulness of antipsychotic medication in the treatment of schizophrenia

Published online by Cambridge University Press:  29 June 2020

Konstantinos N. Fountoulakis Open the ORCID record for Konstantinos N. Fountoulakis [Opens in a new window] ,
Hans-Jurgen Moeller ,
Siegfried Kasper ,
Carol Tamminga ,
Shigeto Yamawaki ,
Rene Kahn ,
Rajiv Tandon ,
Christoph U. Correll Open the ORCID record for Christoph U. Correll [Opens in a new window]  and
Afzal Javed
Konstantinos N. Fountoulakis*
Affiliation:
3rd Department of Psychiatry, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece
Hans-Jurgen Moeller
Affiliation:
Department of Psychiatry, Ludwig Maximilian University of Munich, Munich, Germany
Siegfried Kasper
Affiliation:
Universitätsklinik für Psychiatrie und Psychotherapie, Medizinische Universität Wien, Vienna, Austria
Carol Tamminga
Affiliation:
Department of Psychiatry, UT Southwestern Medical Center, Dallas, Texas, USA
Shigeto Yamawaki
Affiliation:
Center for Brain, Mind and KANSEI Sciences Research, Hiroshima University, Hiroshima, Japan
Rene Kahn
Affiliation:
Department of Psychiatry and Behavioral Health System, Icahn School of Medicine at Mount Sinai, New York, New York, USA
Rajiv Tandon
Affiliation:
Department of Psychiatry, Western Michigan University Homer Stryker M.D. School of Medicine, Kalamazoo, Michigan, USA
Christoph U. Correll
Affiliation:
Department of Psychiatry, Northwell Health, The Zucker Hillside Hospital, Glen Oaks, New York, USA Department of Psychiatry and Molecular Medicine, Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin Berlin, Berlin, Germany
Afzal Javed
Affiliation:
Warwick Medical School, University of Warwick, Coventry, United Kingdom Pakistan Psychiatric Research Centre, Fountain House, Lahore, Pakistan
*
*Author for correspondence: Konstantinos N. Fountoulakis, Email: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

This is a report of a joint World Psychiatric Association/International College of Neuropsychopharmacology (WPA/CINP) workgroup concerning the risk/benefit ratio of antipsychotics in the treatment of schizophrenia. It utilized a selective but, within topic, comprehensive review of the literature, taking into consideration all the recently discussed arguments on the matter and avoiding taking sides when the results in the literature were equivocal. The workgroup’s conclusions suggested that antipsychotics are efficacious both during the acute and the maintenance phase, and that the current data do not support the existence of a supersensitivity rebound psychosis. Long-term treated patients have better overall outcome and lower mortality than those not taking antipsychotics. Longer duration of untreated psychosis and relapses are modestly related to worse outcome. Loss of brain volume is evident already at first episode and concerns loss of neuropil volume rather than cell loss. Progression of volume loss probably happens in a subgroup of patients with worse prognosis. In humans, antipsychotic treatment neither causes nor worsens volume loss, while there are some data in favor for a protective effect. Schizophrenia manifests 2 to 3 times higher mortality vs the general population, and treatment with antipsychotics includes a number of dangers, including tardive dyskinesia and metabolic syndrome; however, antipsychotic treatment is related to lower mortality, including cardiovascular mortality. In conclusion, the literature strongly supports the use of antipsychotics both during the acute and the maintenance phase without suggesting that it is wise to discontinue antipsychotics after a certain period of time. Antipsychotic treatment improves long-term outcomes and lowers overall and specific-cause mortality.

Keywords

Antipsychoticsusefulnessoutcomeschizophrenia
Type
Review
Information
CNS Spectrums , Volume 26 , Issue 6: Special Issue: Functional Neurological Disorder , December 2021 , pp. 562 - 586
Copyright
© The Author(s), 2020. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Kane, JM, Correll, CU. Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry. 2010;71(9):1115–1124.CrossRefGoogle ScholarPubMed
Carlsson, A, Lindqvist, M. Effect of chlorpromazine or haloperidol on formation of 3methoxytyramine and normetanephrine in mouse brain. Acta pharmacologica et toxicologica. 1963;20:140–144.CrossRefGoogle ScholarPubMed
van Rossum, JM. The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. Archives internationales de pharmacodynamie et de therapie. 1966;160(2):492–494.Google ScholarPubMed
Carlsson, A. Arvid Carlsson. In: Squire, L, ed. The History of Neuroscience in Autobiography. Vol 2. San Diego, CA: Academic Press; 1998:28–66.Google Scholar
Carlsson, A. The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol Rev. 1959;11(2, Part 2):490–493.Google ScholarPubMed
Copolov, D. New name for atypical antipsychotics? Am J Psychiatry. 1997;154(3):439.Google ScholarPubMed
Meltzer, HY, Matsubara, S, Lee, JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther. 1989;251(1):238–246.Google ScholarPubMed
Leucht, S, Leucht, C, Huhn, M, et al. Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, bayesian meta-analysis, and meta-regression of efficacy predictors. Am J Psychiatry. 2017;174(10):927–942.CrossRefGoogle ScholarPubMed
Carbon, M, Kane, JM, Leucht, S, Correll, CU. Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. World Psychiatry. 2018;17(3):330–340.CrossRefGoogle ScholarPubMed
Carbon, M, Hsieh, CH, Kane, JM, Correll, CU. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry. 2017;78(3):e264–e278.CrossRefGoogle ScholarPubMed
Kahn, RS, Sommer, IE, Murray, RM, et al. Schizophrenia. Nat Rev Dis Primers. 2015;1:15067.CrossRefGoogle ScholarPubMed
Correll, CU, Rubio, JM, Kane, JM. What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry. 2018;17(2):149–160.CrossRefGoogle ScholarPubMed
Leucht, S, Heres, S, Hamann, J, Kane, JM. Methodological issues in current antipsychotic drug trials. Schizophr Bull. 2008;34(2):275–285.CrossRefGoogle ScholarPubMed
Buchanan, RW, Kreyenbuhl, J, Kelly, DL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36(1):71–93.CrossRefGoogle ScholarPubMed
Gotzsche, PC, Young, AH, Crace, J. Does long term use of psychiatric drugs cause more harm than good? BMJ. 2015;350:h2435CrossRefGoogle ScholarPubMed
Moncrieff, J. Antipsychotic maintenance treatment: time to rethink? PLoS Med. 2015;12(8):e1001861.CrossRefGoogle ScholarPubMed
Whitaker, R. The case against antipsychotic drugs: a 50-year record of doing more harm than good. Med Hypotheses. 2004;62(1):5–13.CrossRefGoogle ScholarPubMed
Wunderink, L, Nieboer, RM, Wiersma, D, Sytema, S, Nienhuis, FJ. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry. 2013;70(9):913–920.CrossRefGoogle ScholarPubMed
Rappaport, M, Hopkins, HK, Hall, K, Belleza, T, Silverman, J. Are there schizophrenics for whom drugs may be unnecessary or contraindicated? Int Pharmacopsychiatry. 1978;13(2):100–111.CrossRefGoogle ScholarPubMed
Calton, T, Ferriter, M, Huband, N, Spandler, H. A systematic review of the Soteria paradigm for the treatment of people diagnosed with schizophrenia. Schizophr Bull. 2008;34(1):181–192.CrossRefGoogle ScholarPubMed
Moncrieff, J. Inconvenient truths about antipsychotics: a response to Goff et al. Mad in America. May 7, 2017. https://www.madinamerica.com/2017/05/inconvenient-truths-about-antipsychotics-a-response-to-goff-et-al/. Accessed July 5, 2018.Google Scholar
Murray, RM, Quattrone, D, Natesan, S, et al. Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics? Br J Psychiatry. 2016;209(5):361–365.CrossRefGoogle ScholarPubMed
Leucht, S, Tardy, M, Komossa, K, Heres, S, Kissling, W, Davis, JM. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2012;(5):CD008016Google Scholar
Leucht, S, Cipriani, A, Spineli, L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–962.CrossRefGoogle ScholarPubMed
Leucht, S, Kissling, W, Davis, JM. Second-generation antipsychotics for schizophrenia: can we resolve the conflict? Psychol Med. 2009;39(10):1591–1602.CrossRefGoogle ScholarPubMed
Leucht, S, Pitschel-Walz, G, Abraham, D, Kissling, W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res. 1999;35(1):51–68.CrossRefGoogle ScholarPubMed
Leucht, S, Arbter, D, Engel, RR, Kissling, W, Davis, JM. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry. 2009;14(4):429–447.CrossRefGoogle ScholarPubMed
Haddad, PM, Correll, CU. The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses. Ther Adv Psychopharmacol. 2018;8(11):303–318.CrossRefGoogle ScholarPubMed
Zhu, Y, Krause, M, Huhn, M, et al. Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses. Lancet Psychiatry. 2017;4(9):694–705.CrossRefGoogle ScholarPubMed
Samara, MT, Nikolakopoulou, A, Salanti, G, Leucht, S. How many patients with schizophrenia do not respond to antipsychotic drugs in the short term? An Analysis Based on individual patient data from randomized controlled trials. Schizophr Bull. 2019;45(3):639–646.CrossRefGoogle Scholar
Leucht, S, Hierl, S, Kissling, W, Dold, M, Davis, JM. Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. Br J Psychiatry. 2012;200(2):97–106.CrossRefGoogle ScholarPubMed
Kishimoto, T, Hagi, K, Nitta, M, Kane, JM, Correll, CU. Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons. World Psychiatry. 2019;18(2):208–224.CrossRefGoogle ScholarPubMed
Fusar-Poli, P, Papanastasiou, E, Stahl, D, et al. Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials. Schizophr Bull. 2015;41(4):892–899.CrossRefGoogle ScholarPubMed
Goldberg, TE, Goldman, RS, Burdick, KE, et al. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry. 2007;64(10):1115–1122.CrossRefGoogle ScholarPubMed
Mishara, AL, Goldberg, TE. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol Psychiatry. 2004;55(10):1013–1022.CrossRefGoogle ScholarPubMed
Nielsen, RE, Levander, S, Kjaersdam Telleus, G, Jensen, SO, Ostergaard Christensen, T, Leucht, S. Second-generation antipsychotic effect on cognition in patients with schizophrenia—a meta-analysis of randomized clinical trials. Acta Psychiatr Scand. 2015;131(3):185–196.CrossRefGoogle ScholarPubMed
Correll, CU, Detraux, J, De Lepeleire, J, De Hert, M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry. 2015;14(2):119–136.CrossRefGoogle ScholarPubMed
Huhn, M, Nikolakopoulou, A, Schneider-Thoma, J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939–951.CrossRefGoogle ScholarPubMed
Schneider-Thoma, J, Efthimiou, O, Bighelli, I, et al. Second-generation antipsychotic drugs and short-term somatic serious adverse events: a systematic review and meta-analysis. Lancet Psychiatry. 2019;6(9):753–765.CrossRefGoogle ScholarPubMed
Solmi, M, Murru, A, Pacchiarotti, I, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag. 2017;13:757–777.CrossRefGoogle ScholarPubMed
Galling, B, Roldan, A, Nielsen, RE, et al. Type 2 diabetes mellitus in youth exposed to antipsychotics: a systematic review and meta-analysis. JAMA Psychiatry. 2016;73(3):247–259.CrossRefGoogle ScholarPubMed
Vancampfort, D, Correll, CU, Galling, B, et al. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. World Psychiatry. 2016;15(2):166–174.CrossRefGoogle ScholarPubMed
Vancampfort, D, Stubbs, B, Mitchell, AJ, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry. 2015;14(3):339–347.CrossRefGoogle ScholarPubMed
Ray, WA, Chung, CP, Murray, KT, Hall, K, Stein, CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360(3):225–235.CrossRefGoogle ScholarPubMed
Correll, CU, Solmi, M, Veronese, N, et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry. 2017;16(2):163–180.CrossRefGoogle ScholarPubMed
Firth, J, Siddiqi, N, Koyanagi, A, et al. The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. Lancet Psychiatry. 2019;6(8):675–712.CrossRefGoogle ScholarPubMed
Ifteni, P, Correll, CU, Burtea, V, Kane, JM, Manu, P. Sudden unexpected death in schizophrenia: autopsy findings in psychiatric inpatients. Schizophr Res. 2014;155(1–3):72–76.CrossRefGoogle ScholarPubMed
Manu, P, Kane, JM, Correll, CU. Sudden deaths in psychiatric patients. J Clin Psychiatry. 2011;72(7):936–941.CrossRefGoogle ScholarPubMed
Stubbs, B, Koyanagi, A, Veronese, N, et al. Physical multimorbidity and psychosis: comprehensive cross sectional analysis including 242,952 people across 48 low- and middle-income countries. BMC Med. 2016;14(1):189.CrossRefGoogle ScholarPubMed
Stubbs, B, Vancampfort, D, Hallgren, M, et al. EPA guidance on physical activity as a treatment for severe mental illness: a meta-review of the evidence and position statement from the European Psychiatric Association (EPA), supported by the International Organization of Physical Therapists in Mental Health (IOPTMH). Eur Psychiatry. 2018;54:124–144.CrossRefGoogle Scholar
Papola, D, Ostuzzi, G, Gastaldon, C, et al. Antipsychotic use and risk of life-threatening medical events: umbrella review of observational studies. Acta Psychiatr Scand. 2019;140(3):227–243.CrossRefGoogle ScholarPubMed
Yang, C, Hao, Z, Tian, J, et al. Does antipsychotic drug use increase the risk of long term mortality? A systematic review and meta-analysis of observational studies. Oncotarget. 2018;9(19):15101–15110.CrossRefGoogle ScholarPubMed
Taipale, H, Mittendorfer-Rutz, E, Alexanderson, K, et al. Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia. Schizophr Res. 2018;197:274–280.CrossRefGoogle Scholar
Taipale, H, Tanskanen, A, Mehtala, J, Vattulainen, P, Correll, CU, Tiihonen, J. 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). World Psychiatry. 2020;19(1):61–68.CrossRefGoogle Scholar
Tiihonen, J, Mittendorfer-Rutz, E, Torniainen, M, Alexanderson, K, Tanskanen, A. Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: an observational follow-up study. Am J Psychiatry. 2016;173(6):600–606.CrossRefGoogle Scholar
Torniainen, M, Mittendorfer-Rutz, E, Tanskanen, A, et al. Antipsychotic treatment and mortality in schizophrenia. Schizophr Bull. 2015;41(3):656–663.CrossRefGoogle Scholar
Vermeulen, JM, van Rooijen, G, van de Kerkhof, MPJ, Sutterland, AL, Correll, CU, de Haan, L. Clozapine and long-term mortality risk in patients with schizophrenia: a systematic review and meta-analysis of studies lasting 1.1-12.5 years. Schizophr Bull. 2019;45(2):315–329.CrossRefGoogle ScholarPubMed
Zhang, JP, Gallego, JA, Robinson, DG, Malhotra, AK, Kane, JM, Correll, CU. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2013;16(6):1205–1218.CrossRefGoogle ScholarPubMed
Lally, J, Ajnakina, O, Di Forti, M, et al. Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. Psychol Med. 2016;46(15):3231–3240.CrossRefGoogle ScholarPubMed
Kane, JM, Agid, O, Baldwin, ML, et al. Clinical guidance on the identification and management of treatment-resistant schizophrenia. J Clin Psychiatry. 2019;80(2):CrossRefGoogle ScholarPubMed
Bola, JR, Lehtinen, K, Aaltonen, J, Rakkolainen, V, Syvalahti, E, Lehtinen, V. Predicting medication-free treatment response in acute psychosis: cross-validation from the Finnish Need-Adapted Project. J Nerv Ment Dis. 2006;194(10):732–739.CrossRefGoogle ScholarPubMed
Huber, G, Gross, G, Schuttler, R, Linz, M. Longitudinal studies of schizophrenic patients. Schizophr Bull. 1980;6(4):592–605.CrossRefGoogle ScholarPubMed
Emsley, R, Chiliza, B, Asmal, L, et al. A randomized, controlled trial of omega-3 fatty acids plus an antioxidant for relapse prevention after antipsychotic discontinuation in first-episode schizophrenia. Schizophr Res. 2014;158(1–3):230–235.CrossRefGoogle ScholarPubMed
Emsley, R, Oosthuizen, P, Koen, L, Niehaus, D, Martinez, L. Comparison of treatment response in second-episode versus first-episode schizophrenia. J Clin Psychopharmacol. 2013;33(1):80–83.CrossRefGoogle ScholarPubMed
Takeuchi, H, Siu, C, Remington, G, et al. Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia. Neuropsychopharmacology. 2019;44(6):1036–1042.CrossRefGoogle ScholarPubMed
Zipursky, RB, Menezes, NM, Streiner, DL. Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review. Schizophr Res. 2014;152(2–3):408–414.CrossRefGoogle ScholarPubMed
Addington, J, Cornblatt, BA, Cadenhead, KS, et al. At clinical high risk for psychosis: outcome for nonconverters. Am J Psychiatry. 2011;168(8):800–805.CrossRefGoogle ScholarPubMed
Rabinowitz, J, Reichenberg, A, Weiser, M, Mark, M, Kaplan, Z, Davidson, M. Cognitive and behavioural functioning in men with schizophrenia both before and shortly after first admission to hospital. Cross-sectional analysis. Br J Psychiatry. 2000;177:26–32.CrossRefGoogle ScholarPubMed
Reichenberg, A, Weiser, M, Rapp, MA, et al. Elaboration on premorbid intellectual performance in schizophrenia: premorbid intellectual decline and risk for schizophrenia. Arch Gen Psychiatry. 2005;62(12):1297–1304.CrossRefGoogle ScholarPubMed
Zhang, T, Xu, L, Tang, X, et al. Real-world effectiveness of antipsychotic treatment in psychosis prevention in a 3-year cohort of 517 individuals at clinical high risk from the SHARP (ShangHai At Risk for Psychosis). Aust N Z J Psychiatry. 2020;54:696–706.CrossRefGoogle Scholar
Bosnjak Kuharic, D, Kekin, I, Hew, J, Rojnic Kuzman, M, Puljak, L. Interventions for prodromal stage of psychosis. Cochrane Database Syst Rev. 2019;2019(11):CD012236.Google Scholar
Yung, AR, Phillips, LJ, Nelson, B, et al. Randomized controlled trial of interventions for young people at ultra high risk for psychosis: 6-month analysis. J Clin Psychiatry. 2011;72(4):430–440.CrossRefGoogle ScholarPubMed
Lee, TY, Kim, SN, Correll, CU, et al. Symptomatic and functional remission of subjects at clinical high risk for psychosis: a 2-year naturalistic observational study. Schizophr Res. 2014;156(2–3):266–271.CrossRefGoogle ScholarPubMed
Liu, CC, Chien, YL, Hsieh, MH, Hwang, TJ, Hwu, HG, Liu, CM. Aripiprazole for drug-naive or antipsychotic-short-exposure subjects with ultra-high risk state and first-episode psychosis: an open-label study. J Clin Psychopharmacol. 2013;33(1):18–23.CrossRefGoogle ScholarPubMed
Kelly, C, Hadjinicolaou, AV, Holt, C, Agius, M, Zaman, R. Meta-analysis of medical and non-medical treatments of the prodromal phase of psychotic illness in at-risk mental states. Psychiatr Danub. 2010;22(suppl 1):S56–S62.Google ScholarPubMed
Davis, KL, Kahn, RS, Ko, G, Davidson, M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry. 1991;148(11):1474–1486.Google ScholarPubMed
Howes, O, McCutcheon, R, Stone, J. Glutamate and dopamine in schizophrenia: an update for the 21st century. J Psychopharmacol. 2015;29(2):97–115.CrossRefGoogle ScholarPubMed
Carlsson, A, Waters, N, Holm-Waters, S, Tedroff, J, Nilsson, M, Carlsson, ML. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu Rev Pharmacol Toxicol. 2001;41(1):237–260.CrossRefGoogle ScholarPubMed
Grace, AA. Gating of information flow within the limbic system and the pathophysiology of schizophrenia. Brain Res Brain Res Rev. 2000;31(2–3):330–341.CrossRefGoogle ScholarPubMed
Howes, OD, Egerton, A, Allan, V, McGuire, P, Stokes, P, Kapur, S. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. Curr Pharm Des. 2009;15(22):2550–2559.CrossRefGoogle ScholarPubMed
Howes, OD, Kapur, S. The dopamine hypothesis of schizophrenia: version III—the final common pathway. Schizophr Bull. 2009;35(3):549–562.CrossRefGoogle ScholarPubMed
Nordstrom, AL, Farde, L, Wiesel, FA, et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry. 1993;33(4):227–235.CrossRefGoogle ScholarPubMed
Boter, H, Peuskens, J, Libiger, J, et al. Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophr Res. 2009;115(2–3):97–103.CrossRefGoogle Scholar
Samaha, AN, Seeman, P, Stewart, J, Rajabi, H, Kapur, S. "Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci. 2007;27(11):2979–2986.CrossRefGoogle ScholarPubMed
Ginovart, N, Wilson, AA, Hussey, D, Houle, S, Kapur, S. D2-receptor upregulation is dependent upon temporal course of D2-occupancy: a longitudinal [11C]-raclopride PET study in cats. Neuropsychopharmacology. 2009;34(3):662–671.CrossRefGoogle ScholarPubMed
Weidenauer, A, Bauer, M, Bartova, L, et al. Behavioral measures of sensitization to repeated d-amphetamine: preliminary data on sex differences in healthy humans. Eur Neuropsychopharmacol. 2016;26:S265–S265.CrossRefGoogle Scholar
Muller, P, Seeman, P. Brain neurotransmitter receptors after long-term haloperidol: dopamine, acetylcholine, serotonin, alpha-noradrenergic and naloxone receptors. Life Sci. 1977;21(12):1751–1758.CrossRefGoogle ScholarPubMed
Moller Nielsen, I, Fjalland, B, Pedersen, V, Nymark, M. Pharmacology of neuroleptics upon repeated administration. Psychopharmacologia. 1974;34(2):95–104.CrossRefGoogle ScholarPubMed
Prien, RF, Levine, J, Switalski, RW. Discontinuation of chemotherapy for chronic schizophrenics. Hosp Community Psychiatry. 1971;22(1):4–7.Google ScholarPubMed
Schooler, NR, Goldberg, SC, Boothe, H, Cole, JO. One year after discharge: community adjustment of schizophrenic patients. Am J Psychiatry. 1967;123(8):986–995.CrossRefGoogle ScholarPubMed
Marsden, CD. Cerebral atrophy and cognitive impairment in chronic schizophrenia. Lancet. 1976;308(7994):1079CrossRefGoogle Scholar
Rupniak, MN, Jenner, P, Marsden, CD. The effect of chronic neuroleptic administration on cerebral dopamine receptor function. Life Sci. 1983;32(20):2289–2311.CrossRefGoogle ScholarPubMed
Chouinard, G. Severe cases of neuroleptic-induced supersensitivity psychosis. Diagnostic criteria for the disorder and its treatment. Schizophr Res. 1991;5(1):21–33.CrossRefGoogle ScholarPubMed
Chouinard, G, Jones, BD. Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. Am J Psychiatry. 1980;137(1):16–21.Google ScholarPubMed
Chouinard, G, Jones, BD, Annable, L. Neuroleptic-induced supersensitivity psychosis. Am J Psychiatry. 1978;135(11):1409–1410.Google ScholarPubMed
Gitlin, M, Nuechterlein, K, Subotnik, KL, et al. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry. 2001;158(11):1835–1842.CrossRefGoogle ScholarPubMed
Takeuchi, H, Kantor, N, Sanches, M, Fervaha, G, Agid, O, Remington, G. One-year symptom trajectories in patients with stable schizophrenia maintained on antipsychotics versus placebo: meta-analysis. Br J Psychiatry. 2017;211(3):137–143.CrossRefGoogle ScholarPubMed
Viguera, AC, Baldessarini, RJ, Hegarty, JD, van Kammen, DP, Tohen, M. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry. 1997;54(1):49–55.CrossRefGoogle ScholarPubMed
Leucht, S, Tardy, M, Komossa, K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379(9831):2063–2071.CrossRefGoogle ScholarPubMed
Tiihonen, J, Tanskanen, A, Taipale, H. 20-year nationwide follow-up study on discontinuation of antipsychotic treatment in first-episode schizophrenia. Am J Psychiatry. 2018;175(8):765–773.CrossRefGoogle ScholarPubMed
Rubio, JM, Taipale, H, Correll, CU, Tanskanen, A, Kane, JM, Tiihonen, J. Psychosis breakthrough on antipsychotic maintenance: results from a nationwide study. Psychol Med. 2020;50:1356–1367.CrossRefGoogle ScholarPubMed
Emsley, R, Asmal, L, Rubio, JM, Correll, CU, Kane, JM. Predictors of psychosis breakthrough during 24 months of long-acting antipsychotic maintenance treatment in first episode schizophrenia. Schizophr Res. 2019;Google ScholarPubMed
Chiappini, S, Schifano, F, Corkery, JM, Guirguis, A. Focus on clozapine withdrawal- and misuse-related cases as reported to the European Medicines Agency (EMA) pharmacovigilance database. Brain Sci. 2020;10(2):105.CrossRefGoogle Scholar
Bastiampillai, T, Juneja, V, Nance, MJ. Clozapine rebound mania. Aust N Z J Psychiatry. 2014;48(1):98–99.CrossRefGoogle ScholarPubMed
Stanilla, JK, de Leon, J, Simpson, GM. Clozapine withdrawal resulting in delirium with psychosis: a report of three cases. J Clin Psychiatry. 1997;58(6):252–255.CrossRefGoogle ScholarPubMed
Stevenson, E, Schembri, F, Green, DM, Burns, JD. Serotonin syndrome associated with clozapine withdrawal. JAMA Neurol. 2013;70(8):1054–1055.CrossRefGoogle ScholarPubMed
Bilbily, J, McCollum, B, de Leon, J. Catatonia secondary to sudden clozapine withdrawal: a case with three repeated episodes and a literature review. Case Rep Psychiatry. 2017;2017:2402731.Google ScholarPubMed
Boazak, M, Cotes, RO, Potvin, H, Decker, AM, Schwartz, AC. Catatonia due to clozapine withdrawal: a case report and literature review. Psychosomatics. 2019;60(4):421–427.CrossRefGoogle ScholarPubMed
Kumar, S, Sur, S, Singh, A. Catatonia following abrupt stoppage of clozapine. Aust N Z J Psychiatry. 2011;45(6):499CrossRefGoogle ScholarPubMed
Margetic, B, Aukst-Margetic, B. Neuroleptic malignant syndrome and clozapine withdrawal at the same time? Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(1):145–147.CrossRefGoogle ScholarPubMed
Hazari, N, Kate, N, Grover, S. Clozapine and tardive movement disorders: a review. Asian J Psychiatr. 2013;6(6):439–451.CrossRefGoogle ScholarPubMed
Ahmed, S, Chengappa, KN, Naidu, VR, Baker, RW, Parepally, H, Schooler, NR. Clozapine withdrawal-emergent dystonias and dyskinesias: a case series. J Clin Psychiatry. 1998;59(9):472–477.CrossRefGoogle ScholarPubMed
Galova, A, Berney, P, Desmeules, J, Sergentanis, I, Besson, M. A case report of cholinergic rebound syndrome following abrupt low-dose clozapine discontinuation in a patient with type I bipolar affective disorder. BMC Psychiatry. 2019;19(1):73CrossRefGoogle Scholar
Sarma, S, Chetia, D, Raha, B, Agarwal, G. Clozapine withdrawal emergent dystonia, oculogyric crisis and rebound psychosis in a single patient. Ther Adv Psychopharmacol. 2016;6(2):145–146.CrossRefGoogle ScholarPubMed
Carpenter, WT, McGlashan, TH, Strauss, JS. The treatment of acute schizophrenia without drugs: an investigation of some current assumptions. Am J Psychiatry. 1977;134(1):14–20.Google ScholarPubMed
Moncrieff, J. Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr Scand. 2006;114(1):3–13.CrossRefGoogle ScholarPubMed
Goff, DC, Falkai, P, Fleischhacker, WW, et al. The long-term effects of antipsychotic medication on clinical course in schizophrenia. Am J Psychiatry. 2017;174(9):840–849.CrossRefGoogle Scholar
Francey, SM, Nelson, B, Thompson, A, et al. Who needs antipsychotic medication in the earliest stages of psychosis? A reconsideration of benefits, risks, neurobiology and ethics in the era of early intervention. Schizophr Res. 2010;119(1–3):1–10.CrossRefGoogle ScholarPubMed
Sohler, N, Adams, BG, Barnes, DM, Cohen, GH, Prins, SJ, Schwartz, S. Weighing the evidence for harm from long-term treatment with antipsychotic medications: a systematic review. Am J Orthopsychiatry. 2016;86(5):477–485.CrossRefGoogle ScholarPubMed
Wyatt, RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull. 1991;17(2):325–351.CrossRefGoogle ScholarPubMed
May, PR, Tuma, AH, Yale, C, Potepan, P, Dixon, WJ. Schizophrenia—a follow-up study of results of treatment. Arch Gen Psychiatry. 1976;33(4):481–486.CrossRefGoogle ScholarPubMed
McWalter, HS, Mercer, R, Sutherland, M, Watt, A. Outcomes of treatment of schizophrenia in a north-east Scottish mental hospital. Am J Psychiat. 1961;118(6):529–533.CrossRefGoogle Scholar
Odegard, O. Pattern of discharge from Norwegian psychiatric hospitals before and after the introduction of the psychotropic drugs. Am J Psychiatry. 1964;120(8):772–778.CrossRefGoogle ScholarPubMed
Peterson, DB, Olson, GW. First admitted schizophrenics in drug era; follow-up Anoka schizophrenic cohort, 1956-1958. Arch Gen Psychiatry. 1964;11(2):137–144.CrossRefGoogle ScholarPubMed
Pritchard, M. Prognosis of schizophrenia before and after pharmacotherapy: I. Short term outcome. Br J Psychiatry. 1967;113(505):1345–1352.CrossRefGoogle ScholarPubMed
Zhou, Y, Li, G, Li, D, Cui, H, Ning, Y. Dose reduction of risperidone and olanzapine can improve cognitive function and negative symptoms in stable schizophrenic patients: a single-blinded, 52-week, randomized controlled study. J Psychopharmacol. 2018;32(5):524–532.CrossRefGoogle ScholarPubMed
Hegarty, JD, Baldessarini, RJ, Tohen, M, Waternaux, C. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Schizophr Res. 1993;9(2–3):134CrossRefGoogle Scholar
Hegarty, JD, Baldessarini, RJ, Tohen, M, Waternaux, C, Oepen, G. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry. 1994;151(10):1409–1416.Google ScholarPubMed
Jaaskelainen, E, Juola, P, Hirvonen, N, et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull. 2013;39(6):1296–1306.CrossRefGoogle Scholar
Alem, A, Kebede, D, Fekadu, A, et al. Clinical course and outcome of schizophrenia in a predominantly treatment-naive cohort in rural Ethiopia. Schizophr Bull. 2009;35(3):646–654.CrossRefGoogle Scholar
Kurihara, T, Kato, M, Reverger, R, Tirta, IGR, Kashima, H. Never-treated patients with schizophrenia in the developing country of Bali. Schizophr Res. 2005;79(2–3):307–313.CrossRefGoogle ScholarPubMed
Ran, MS, Weng, X, Chan, CL, et al. Different outcomes of never-treated and treated patients with schizophrenia: 14-year follow-up study in rural China. Br J Psychiatry. 2015;207(6):495–500.CrossRefGoogle ScholarPubMed
Padmavathi, R, Rajkumar, S, Srinivasan, TN. Schizophrenic patients who were never treated--a study in an Indian urban community. Psychol Med. 1998;28(5):1113–1117.CrossRefGoogle Scholar
Wunderink, L, Nienhuis, FJ, Sytema, S, Slooff, CJ, Knegtering, R, Wiersma, D. Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. J Clin Psychiatry. 2007;68(5):654–661.CrossRefGoogle ScholarPubMed
Gaebel, W, Riesbeck, M, Wolwer, W, et al. Predictors for symptom re-exacerbation after targeted stepwise drug discontinuation in first-episode schizophrenia: results of the first-episode study within the German Research Network on Schizophrenia. Schizophr Res. 2016;170(1):168–176.CrossRefGoogle Scholar
Gaebel, W, Riesbeck, M, Wolwer, W, et al. Relapse prevention in first-episode schizophrenia—maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry. 2011;72(2):205–218.CrossRefGoogle Scholar
Cheung, HK. Schizophrenics fully remitted on neuroleptics for 3-5 years—to stop or continue drugs? Br J Psychiatry. 1981;138:490–494.CrossRefGoogle ScholarPubMed
Sampath, G, Shah, A, Krska, J, Soni, SD. Neuroleptic discontinuation in the very stable schizophrenic patient: relapse rates and serum neuroleptic levels. Hum Psychopharmacol. 1992;7(4):255–264.CrossRefGoogle Scholar
Fenton, WS, McGlashan, TH. Sustained remission in drug-free schizophrenic patients. Am J Psychiatry. 1987;144(10):1306–1309.Google ScholarPubMed
Harrison, G, Hopper, K, Craig, T, et al. Recovery from psychotic illness: a 15- and 25-year international follow-up study. Br J Psychiatry. 2001;178(06):506–517.CrossRefGoogle ScholarPubMed
Harrow, M, Grossman, LS, Jobe, TH, Herbener, ES. Do patients with schizophrenia ever show periods of recovery? A 15-year multi-follow-up study. Schizophr Bull. 2005;31(3):723–734.CrossRefGoogle ScholarPubMed
Harrow, M, Jobe, TH, Faull, RN. Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime? A 20-year longitudinal study. Psychol Med. 2012;42(10):2145–2155.CrossRefGoogle ScholarPubMed
Harrow, M, Jobe, TH, Faull, RN. Does treatment of schizophrenia with antipsychotic medications eliminate or reduce psychosis? A 20-year multi-follow-up study. Psychol Med. 2014;44(14):3007–3016.CrossRefGoogle ScholarPubMed
Harrow, M, Jobe, TH, Faull, RN, Yang, J. A 20-year multi-followup longitudinal study assessing whether antipsychotic medications contribute to work functioning in schizophrenia. Psychiatry Res. 2017;256:267–274.CrossRefGoogle Scholar
Hui, CLM, Honer, WG, Lee, EHM, et al. Long-term effects of discontinuation from antipsychotic maintenance following first-episode schizophrenia and related disorders: a 10 year follow-up of a randomised, double-blind trial. Lancet Psychiatry. 2018;5(5):432–442.CrossRefGoogle ScholarPubMed
Kotov, R, Fochtmann, L, Li, K, et al. Declining clinical course of psychotic disorders over the two decades following first hospitalization: evidence from the Suffolk County Mental Health Project. Am J Psychiatry. 2017;174(11):1064–1074.CrossRefGoogle ScholarPubMed
Leff, J, Sartorius, N, Jablensky, A, Korten, A, Ernberg, G. The International Pilot Study of Schizophrenia: five-year follow-up findings. Psychol Med. 1992;22(1):131–145.CrossRefGoogle ScholarPubMed
Moilanen, J, Haapea, M, Miettunen, J, et al. Characteristics of subjects with schizophrenia spectrum disorder with and without antipsychotic medication—a 10-year follow-up of the Northern Finland 1966 Birth Cohort study. Eur Psychiatry. 2013;28(1):53–58.CrossRefGoogle ScholarPubMed
Morgan, C, Lappin, J, Heslin, M, et al. Reappraising the long-term course and outcome of psychotic disorders: the AESOP-10 study. Psychol Med. 2014;44(13):2713–2726.CrossRefGoogle ScholarPubMed
Revier, CJ, Reininghaus, U, Dutta, R, et al. Ten-year outcomes of first-episode psychoses in the MRC AESOP-10 Study. J Nerv Ment Dis. 2015;203(5):379–386.CrossRefGoogle ScholarPubMed
Tiihonen, J, Wahlbeck, K, Lonnqvist, J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ. 2006;333(7561):224CrossRefGoogle Scholar
Tiihonen, J, Lonnqvist, J, Wahlbeck, K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009;374(9690):620–627.CrossRefGoogle Scholar
Wils, RS, Gotfredsen, DR, Hjorthoj, C, et al. Antipsychotic medication and remission of psychotic symptoms 10years after a first-episode psychosis. Schizophr Res. 2017;182:42–48.CrossRefGoogle ScholarPubMed
Sampson, S, Mansour, M, Maayan, N, Soares-Weiser, K, Adams, CE. Intermittent drug techniques for schizophrenia. Cochrane Database Syst Rev. 2013;20(7):CD006196.Google Scholar
World Health Organization. Schizophrenia: An International Follow Up Study. Chichester: John Wiley & Sons; 1979.Google Scholar
Cohen, A, Patel, V, Thara, R, Gureje, O. Questioning an axiom: better prognosis for schizophrenia in the developing world? Schizophr Bull. 2008;34(2):229–244.CrossRefGoogle ScholarPubMed
Karagianis, J, Novick, D, Pecenak, J, et al. Worldwide-Schizophrenia Outpatient Health Outcomes (W-SOHO): baseline characteristics of pan-regional observational data from more than 17,000 patients. Int J Clin Pract. 2009;63(11):1578–1588.CrossRefGoogle ScholarPubMed
Kulhara, P, Shah, R, Grover, S. Is the course and outcome of schizophrenia better in the 'developing' world? Asian J Psychiatr. 2009;2(2):55–62.CrossRefGoogle ScholarPubMed
Padma, TV. Developing countries: the outcomes paradox. Nature. 2014;508(7494):S14–S15.CrossRefGoogle ScholarPubMed
Harrow, M, Jobe, TH. Long-term antipsychotic treatment of schizophrenia: does it help or hurt over a 20-year period? World Psychiatry. 2018;17(2):162–163.CrossRefGoogle ScholarPubMed
De Hert, M, Correll, CU, Cohen, D. Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study. Schizophr Res. 2010;117(1):68–74.CrossRefGoogle ScholarPubMed
Steingard, S. Duration of untreated psychosis revisited: response to the Goff Paper. Mad in America. November 13, 2017. https://www.madinamerica.com/2017/11/duration-of-untreated-psychosis-response-goff-paper/. Accessed July 5, 2018.Google Scholar
Whitaker, R. Thou shall not criticize our drugs. Mad in America. September 22, 2017. https://www.madinamerica.com/2017/09/thou-shall-not-criticize-our-drugs/. Accessed July 5, 2018.Google Scholar
Menezes, NM, Arenovich, T, Zipursky, RB. A systematic review of longitudinal outcome studies of first-episode psychosis. Psychol Med. 2006;36(10):1349–1362.CrossRefGoogle ScholarPubMed
Austin, SF, Mors, O, Budtz-Jorgensen, E, et al. Long-term trajectories of positive and negative symptoms in first episode psychosis: a 10year follow-up study in the OPUS cohort. Schizophr Res. 2015;168(1–2):84–91.CrossRefGoogle ScholarPubMed
Marshall, M, Lewis, S, Lockwood, A, Drake, R, Jones, P, Croudace, T. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry. 2005;62(9):975–983.CrossRefGoogle ScholarPubMed
Penttila, M, Jaaskelainen, E, Hirvonen, N, Isohanni, M, Miettunen, J. Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2014;205(2):88–94.CrossRefGoogle ScholarPubMed
Perkins, DO, Gu, H, Boteva, K, Lieberman, JA. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry. 2005;162(10):1785–1804.CrossRefGoogle ScholarPubMed
Addington, J, Van Mastrigt, S, Addington, D. Duration of untreated psychosis: impact on 2-year outcome. Psychol Med. 2004;34(2):277–284.CrossRefGoogle ScholarPubMed
Albert, N, Melau, M, Jensen, H, Hastrup, LH, Hjorthoj, C, Nordentoft, M. The effect of duration of untreated psychosis and treatment delay on the outcomes of prolonged early intervention in psychotic disorders. NPJ Schizophr. 2017;3(1):34CrossRefGoogle ScholarPubMed
Barnes, TR, Leeson, VC, Mutsatsa, SH, Watt, HC, Hutton, SB, Joyce, EM. Duration of untreated psychosis and social function: 1-year follow-up study of first-episode schizophrenia. Br J Psychiatry. 2008;193(3):203–209.CrossRefGoogle ScholarPubMed
Bottlender, R, Sato, T, Jager, M, Groll, C, Strauss, A, Moller, HJ. The impact of duration of untreated psychosis and premorbid functioning on outcome of first inpatient treatment in schizophrenic and schizoaffective patients. Eur Arch Psychiatry Clin Neurosci. 2002;252(5):226–231.CrossRefGoogle ScholarPubMed
Goff, DC, Zeng, B, Ardekani, BA, et al. Association of hippocampal atrophy with duration of untreated psychosis and molecular biomarkers during initial antipsychotic treatment of first-episode psychosis. JAMA Psychiatry. 2018;75(4):370–378.CrossRefGoogle ScholarPubMed
Guo, X, Li, J, Wei, Q, et al. Duration of untreated psychosis is associated with temporal and occipitotemporal gray matter volume decrease in treatment naive schizophrenia. PLoS One. 2013;8(12):e83679CrossRefGoogle ScholarPubMed
Hegelstad, WT, Larsen, TK, Auestad, B, et al. Long-term follow-up of the TIPS early detection in psychosis study: effects on 10-year outcome. Am J Psychiatry. 2012;169(4):374–380.CrossRefGoogle ScholarPubMed
Ho, BC, Alicata, D, Ward, J, et al. Untreated initial psychosis: relation to cognitive deficits and brain morphology in first-episode schizophrenia. Am J Psychiatry. 2003;160(1):142–148.CrossRefGoogle ScholarPubMed
Melle, I, Larsen, TK, Haahr, U, et al. Prevention of negative symptom psychopathologies in first-episode schizophrenia: two-year effects of reducing the duration of untreated psychosis. Arch Gen Psychiatry. 2008;65(6):634–640.CrossRefGoogle ScholarPubMed
Primavera, D, Bandecchi, C, Lepori, T, Sanna, L, Nicotra, E, Carpiniello, B. Does duration of untreated psychosis predict very long term outcome of schizophrenic disorders? Results of a retrospective study. Ann Gen Psychiatry. 2012;11(1):21CrossRefGoogle ScholarPubMed
Qin, H, Zhang, J, Wang, Z, et al. Duration of untreated psychosis and clinical outcomes of first-episode schizophrenia: a 4-year follow-up study. Shanghai Arch Psychiatry. 2014;26(1):42–48.Google ScholarPubMed
Ran, MS, Xiao, Y, Chui, CHK, et al. Duration of untreated psychosis (DUP) and outcome of people with schizophrenia in rural China: 14-year follow-up study. Psychiatry Res. 2018;267:340–345.CrossRefGoogle ScholarPubMed
Sullivan, SA, Carroll, R, Peters, TJ, et al. Duration of untreated psychosis and clinical outcomes of first episode psychosis: an observational and an instrumental variables analysis. Early Interv Psychiatry. 2019;13(4):841–847.CrossRefGoogle Scholar
Gøtzsche, P. Psychiatry ignores an elephant in the room. Mad in America. September 21, 2017. https://www.madinamerica.com/2017/09/psychiatry-ignores-elephant-room/. Accessed July 5, 2018.Google Scholar
Melle, I, Olav Johannesen, J, Haahr, UH, et al. Causes and predictors of premature death in first-episode schizophrenia spectrum disorders. World Psychiatry. 2017;16(2):217–218.CrossRefGoogle ScholarPubMed
Bora, E, Yalincetin, B, Akdede, BB, Alptekin, K. Duration of untreated psychosis and neurocognition in first-episode psychosis: a meta-analysis. Schizophr Res. 2018;193:3–10.CrossRefGoogle ScholarPubMed
Anderson, KK, Rodrigues, M, Mann, K, et al. Minimal evidence that untreated psychosis damages brain structures: a systematic review. Schizophr Res. 2015;162(1–3):222–233.CrossRefGoogle ScholarPubMed
Jonas, KG, Fochtmann, LJ, Perlman, G, et al. Lead-time bias confounds association between duration of untreated psychosis and illness course in schizophrenia. Am J Psychiatry. 2020;177(4):327–334.CrossRefGoogle Scholar
Fountoulakis, KN, Dragioti, E, Theofilidis, AT, et al. Staging of schizophrenia with the use of PANSS: an international multi-center study. Int J Neuropsychopharmacol. 2019;22(11):681–697.CrossRefGoogle ScholarPubMed
Robinson, D, Woerner, MG, Alvir, JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56(3):241–247.CrossRefGoogle ScholarPubMed
Lieberman, J, Jody, D, Geisler, S, et al. Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry. 1993;50(5):369–376.CrossRefGoogle ScholarPubMed
Lieberman, JA, Alvir, JM, Koreen, A, et al. Psychobiologic correlates of treatment response in schizophrenia. Neuropsychopharmacology. 1996;14(3 suppl):13S–21S.CrossRefGoogle Scholar
Wyatt, RJ. Research in schizophrenia and the discontinuation of antipsychotic medications. Schizophr Bull. 1997;23(1):3–9.CrossRefGoogle ScholarPubMed
Emsley, R, Oosthuizen, PP, Koen, L, Niehaus, DJ, Martinez, G. Symptom recurrence following intermittent treatment in first-episode schizophrenia successfully treated for 2 years: a 3-year open-label clinical study. J Clin Psychiatry. 2012;73(4):e541–e547.CrossRefGoogle ScholarPubMed
McEvoy, JP, Hogarty, GE, Steingard, S. Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry. 1991;48(8):739–745.CrossRefGoogle ScholarPubMed
Birchwood, M, Smith, J, Macmillan, F, et al. Predicting relapse in schizophrenia: the development and implementation of an early signs monitoring system using patients and families as observers, a preliminary investigation. Psychol Med. 1989;19(3):649–656.CrossRefGoogle ScholarPubMed
Wiersma, D, Nienhuis, FJ, Slooff, CJ, Giel, R. Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort. Schizophr Bull. 1998;24(1):75–85.CrossRefGoogle ScholarPubMed
Emsley, R, Nuamah, I, Hough, D, Gopal, S. Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia. Schizophr Res. 2012;138(1):29–34.CrossRefGoogle Scholar
Carbon, M, Correll, CU. Clinical predictors of therapeutic response to antipsychotics in schizophrenia. Dialogues Clin Neurosci. 2014;16(4):505–524.Google Scholar
Curson, DA, Barnes, TR, Bamber, RW, Platt, SD, Hirsch, SR, Duffy, JC. Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine/placebo trial. III. Relapse postponement or relapse prevention? The implications for long-term outcome. Br J Psychiatry. 1985;146(5):474–480.CrossRefGoogle ScholarPubMed
Andreasen, NC, Liu, D, Ziebell, S, Vora, A, Ho, BC. Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. Am J Psychiatry. 2013;170(6):609–615.CrossRefGoogle ScholarPubMed
Cannon, M, Jones, P, Huttunen, MO, et al. School performance in Finnish children and later development of schizophrenia: a population-based longitudinal study. Arch Gen Psychiatry. 1999;56(5):457–463.CrossRefGoogle ScholarPubMed
Fuller, R, Nopoulos, P, Arndt, S, O'Leary, D, Ho, BC, Andreasen, NC. Longitudinal assessment of premorbid cognitive functioning in patients with schizophrenia through examination of standardized scholastic test performance. Am J Psychiatry. 2002;159(7):1183–1189.CrossRefGoogle ScholarPubMed
McGlashan, TH. Is active psychosis neurotoxic? Schizophr Bull. 2006;32(4):609–613.CrossRefGoogle ScholarPubMed
AlAqeel, B, Margolese, HC. Remission in schizophrenia: critical and systematic review. Harv Rev Psychiatry. 2012;20(6):281–297.CrossRefGoogle ScholarPubMed
de Haan, L, Nimwegen, L, Amelsvoort, T, Dingemans, P, Linszen, D. Improvement of subjective well-being and enduring symptomatic remission, a 5-year follow-up of first episode schizophrenia. Pharmacopsychiatry. 2008;41(4):125–128.CrossRefGoogle ScholarPubMed
Kelly, DL, Weiner, E, Ball, MP, McMahon, RP, Carpenter, WT, Buchanan, RW. Remission in schizophrenia: the relationship to baseline symptoms and changes in symptom domains during a one-year study. J Psychopharmacol. 2009;23(4):436–441.CrossRefGoogle ScholarPubMed
Emsley, R, Rabinowitz, J, Medori, R, Early Psychosis Global Working Group. Remission in early psychosis: rates, predictors, and clinical and functional outcome correlates. Schizophr Res. 2007;89(1–3):129–139.CrossRefGoogle ScholarPubMed
Zhu, Y, Li, C, Huhn, M, et al. How well do patients with a first episode of schizophrenia respond to antipsychotics: a systematic review and meta-analysis. Eur Neuropsychopharmacol. 2017;27(9):835–844.CrossRefGoogle ScholarPubMed
Johnstone, EC, Crow, TJ, Frith, CD, Husband, J, Kreel, L. Cerebral ventricular size and cognitive impairment in chronic schizophrenia. Lancet. 1976;2(7992):924–926.CrossRefGoogle ScholarPubMed
Hill, D. Cerebral atrophy and cognitive impairment in chronic schizophrenia. Lancet. 1976;2(7995):1132CrossRefGoogle ScholarPubMed
Baare, WF, van Oel, CJ, Hulshoff Pol, HE, et al. Volumes of brain structures in twins discordant for schizophrenia. Arch Gen Psychiatry. 2001;58(1):33–40.CrossRefGoogle Scholar
Veijola, J, Guo, JY, Moilanen, JS, et al. Longitudinal changes in total brain volume in schizophrenia: relation to symptom severity, cognition and antipsychotic medication. PLoS One. 2014;9(7):e101689CrossRefGoogle ScholarPubMed
van Haren, NE, Schnack, HG, Cahn, W, et al. Changes in cortical thickness during the course of illness in schizophrenia. Arch Gen Psychiatry. 2011;68(9):871–880.CrossRefGoogle Scholar
Kubota, M, van Haren, NE, Haijma, SV, et al. Association of IQ changes and progressive brain changes in patients with schizophrenia. JAMA Psychiatry. 2015;72(8):803–812.CrossRefGoogle ScholarPubMed
Boonstra, G, van Haren, NE, Schnack, HG, et al. Brain volume changes after withdrawal of atypical antipsychotics in patients with first-episode schizophrenia. J Clin Psychopharmacol. 2011;31(2):146–153.CrossRefGoogle ScholarPubMed
Lieberman, J, Chakos, M, Wu, H, et al. Longitudinal study of brain morphology in first episode schizophrenia. Biol Psychiatry. 2001;49(6):487–499.CrossRefGoogle ScholarPubMed
Toulopoulou, T, Grech, A, Morris, RG, et al. The relationship between volumetric brain changes and cognitive function: a family study on schizophrenia. Biol Psychiatry. 2004;56(6):447–453.CrossRefGoogle Scholar
Koutsouleris, N, Borgwardt, S, Meisenzahl, EM, Bottlender, R, Moller, HJ, Riecher-Rossler, A. Disease prediction in the at-risk mental state for psychosis using neuroanatomical biomarkers: results from the FePsy study. Schizophr Bull. 2012;38(6):1234–1246.CrossRefGoogle Scholar
Koutsouleris, N, Kambeitz-Ilankovic, L, Ruhrmann, S, et al. Prediction models of functional outcomes for individuals in the clinical high-risk state for psychosis or with recent-onset depression: a multimodal, multisite machine learning analysis. JAMA Psychiatry. 2018;75(11):1156–1172.CrossRefGoogle ScholarPubMed
Haijma, SV, Van Haren, N, Cahn, W, Koolschijn, PC, Hulshoff Pol, HE, Kahn, RS. Brain volumes in schizophrenia: a meta-analysis in over 18 000 subjects. Schizophr Bull. 2013;39(5):1129–1138.CrossRefGoogle ScholarPubMed
Selemon, LD, Goldman-Rakic, PS. The reduced neuropil hypothesis: a circuit based model of schizophrenia. Biol Psychiatry. 1999;45(1):17–25.CrossRefGoogle ScholarPubMed
Arnold, SE, Trojanowski, JQ, Gur, RE, Blackwell, P, Han, LY, Choi, C. Absence of neurodegeneration and neural injury in the cerebral cortex in a sample of elderly patients with schizophrenia. Arch Gen Psychiatry. 1998;55(3):225–232.CrossRefGoogle Scholar
Bogerts, B, Meertz, E, Schonfeldt-Bausch, R. Basal ganglia and limbic system pathology in schizophrenia. A morphometric study of brain volume and shrinkage. Arch Gen Psychiatry. 1985;42(8):784–791.CrossRefGoogle ScholarPubMed
Bogerts, B, Falkai, P, Haupts, M, et al. Post-mortem volume measurements of limbic system and basal ganglia structures in chronic schizophrenics. Initial results from a new brain collection. Schizophr Res. 1990;3(5–6):295–301.CrossRefGoogle ScholarPubMed
Chana, G, Landau, S, Beasley, C, Everall, IP, Cotter, D. Two-dimensional assessment of cytoarchitecture in the anterior cingulate cortex in major depressive disorder, bipolar disorder, and schizophrenia: evidence for decreased neuronal somal size and increased neuronal density. Biol Psychiatry. 2003;53(12):1086–1098.CrossRefGoogle ScholarPubMed
Hof, PR, Haroutunian, V, Friedrich, VL Jr., et al. Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophrenia. Biol Psychiatry. 2003;53(12):1075–1085.CrossRefGoogle Scholar
Pakkenberg, B. Total nerve cell number in neocortex in chronic schizophrenics and controls estimated using optical disectors. Biol Psychiatry. 1993;34(11):768–772.CrossRefGoogle ScholarPubMed
Selemon, LD, Rajkowska, G, Goldman-Rakic, PS. Abnormally high neuronal density in the schizophrenic cortex. A morphometric analysis of prefrontal area 9 and occipital area 17. Arch Gen Psychiatry. 1995;52(10):805–818; discussion 819–820.CrossRefGoogle ScholarPubMed
Selemon, LD, Kleinman, JE, Herman, MM, Goldman-Rakic, PS. Smaller frontal gray matter volume in postmortem schizophrenic brains. Am J Psychiatry. 2002;159(12):1983–1991.CrossRefGoogle ScholarPubMed
Stark, AK, Uylings, HB, Sanz-Arigita, E, Pakkenberg, B. Glial cell loss in the anterior cingulate cortex, a subregion of the prefrontal cortex, in subjects with schizophrenia. Am J Psychiatry. 2004;161(5):882–888.CrossRefGoogle ScholarPubMed
Thune, JJ, Uylings, HB, Pakkenberg, B. No deficit in total number of neurons in the prefrontal cortex in schizophrenics. J Psychiatr Res. 2001;35(1):15–21.CrossRefGoogle ScholarPubMed
McIntosh, AM, Owens, DC, Moorhead, WJ, et al. Longitudinal volume reductions in people at high genetic risk of schizophrenia as they develop psychosis. Biol Psychiatry. 2011;69(10):953–958.CrossRefGoogle ScholarPubMed
Radua, J, Borgwardt, S, Crescini, A, et al. Multimodal meta-analysis of structural and functional brain changes in first episode psychosis and the effects of antipsychotic medication. Neurosci Biobehav Rev. 2012;36(10):2325–2333.CrossRefGoogle ScholarPubMed
van Haren, NE, Hulshoff Pol, HE, Schnack, HG, et al. Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study. Neuropsychopharmacology. 2007;32(10):2057–2066.CrossRefGoogle ScholarPubMed
Ho, BC, Andreasen, NC, Ziebell, S, Pierson, R, Magnotta, V. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch Gen Psychiatry. 2011;68(2):128–137.CrossRefGoogle ScholarPubMed
Ho, BC, Andreasen, NC, Dawson, JD, Wassink, TH. Association between brain-derived neurotrophic factor Val66Met gene polymorphism and progressive brain volume changes in schizophrenia. Am J Psychiatry. 2007;164(12):1890–1899.CrossRefGoogle Scholar
Ahmed, M, Cannon, DM, Scanlon, C, et al. Progressive brain atrophy and cortical thinning in schizophrenia after commencing clozapine treatment. Neuropsychopharmacology. 2015;40(10):2409–2417.CrossRefGoogle ScholarPubMed
Vita, A, De Peri, L, Deste, G, Sacchetti, E. Progressive loss of cortical gray matter in schizophrenia: a meta-analysis and meta-regression of longitudinal MRI studies. Transl Psychiatry. 2012;2:e190CrossRefGoogle ScholarPubMed
Van Haren, NE, Cahn, W, Hulshoff Pol, HE, Kahn, RS. Confounders of excessive brain volume loss in schizophrenia. Neurosci Biobehav Rev. 2013;37(10 Pt 1):2418–2423.CrossRefGoogle Scholar
Ho, BC, Andreasen, NC, Nopoulos, P, Arndt, S, Magnotta, V, Flaum, M. Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia. Arch Gen Psychiatry. 2003;60(6):585–594.CrossRefGoogle Scholar
Vita, A, De Peri, L, Deste, G, Barlati, S, Sacchetti, E. The effect of antipsychotic treatment on cortical gray matter changes in schizophrenia: does the class matter? A meta-analysis and meta-regression of longitudinal magnetic resonance imaging studies. Biol Psychiatry. 2015;78(6):403–412.CrossRefGoogle Scholar
Zipursky, RB, Reilly, TJ, Murray, RM. The myth of schizophrenia as a progressive brain disease. Schizophr Bull. 2013;39(6):1363–1372.CrossRefGoogle ScholarPubMed
Murray, RM. Mistakes i have made in my research career. Schizophr Bull. 2017;43(2):253–256.Google Scholar
Dorph-Petersen, KA, Pierri, JN, Perel, JM, Sun, Z, Sampson, AR, Lewis, DA. The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys. Neuropsychopharmacology. 2005;30(9):1649–1661.CrossRefGoogle ScholarPubMed
Konopaske, GT, Dorph-Petersen, KA, Pierri, JN, Wu, Q, Sampson, AR, Lewis, DA. Effect of chronic exposure to antipsychotic medication on cell numbers in the parietal cortex of macaque monkeys. Neuropsychopharmacology. 2007;32(6):1216–1223.CrossRefGoogle ScholarPubMed
Vernon, AC, Natesan, S, Modo, M, Kapur, S. Effect of chronic antipsychotic treatment on brain structure: a serial magnetic resonance imaging study with ex vivo and postmortem confirmation. Biol Psychiatry. 2011;69(10):936–944.CrossRefGoogle ScholarPubMed
Dean, CE. Antipsychotic-associated neuronal changes in the brain: toxic, therapeutic, or irrelevant to the long-term outcome of schizophrenia? Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(2):174–189.CrossRefGoogle ScholarPubMed
Harrison, PJ. The neuropathological effects of antipsychotic drugs. Schizophr Res. 1999;40(2):87–99.CrossRefGoogle ScholarPubMed
Schmitt, A, Steyskal, C, Bernstein, HG, et al. Stereologic investigation of the posterior part of the hippocampus in schizophrenia. Acta Neuropathol. 2009;117(4):395–407.CrossRefGoogle Scholar
Falkai, P, Malchow, B, Wetzestein, K, et al. Decreased oligodendrocyte and neuron number in anterior hippocampal areas and the entire hippocampus in schizophrenia: a stereological postmortem study. Schizophr Bull. 2016;42(suppl 1):S4–S12.CrossRefGoogle ScholarPubMed
van Kesteren, CF, Gremmels, H, de Witte, LD, et al. Immune involvement in the pathogenesis of schizophrenia: a meta-analysis on postmortem brain studies. Transl Psychiatry. 2017;7(3):e1075.CrossRefGoogle ScholarPubMed
Harrison, PJ. The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain. 1999;122(Pt 4):593–624.CrossRefGoogle ScholarPubMed
Bree, AJ, Puente, EC, Daphna-Iken, D, Fisher, SJ. Diabetes increases brain damage caused by severe hypoglycemia. Am J Physiol Endocrinol Metab. 2009;297(1):E194–E201.CrossRefGoogle ScholarPubMed
Auer, RN. Hypoglycemic brain damage. Metab Brain Dis. 2004;19(3–4):169–175.CrossRefGoogle ScholarPubMed
Rhee, SY. Hypoglycemia and dementia. Endocrinol Metab. 2017;32(2):195–199.CrossRefGoogle ScholarPubMed
Puente, EC, Silverstein, J, Bree, AJ, et al. Recurrent moderate hypoglycemia ameliorates brain damage and cognitive dysfunction induced by severe hypoglycemia. Diabetes. 2010;59(4):1055–1062.CrossRefGoogle ScholarPubMed
Garver, DL, Holcomb, JA, Christensen, JD. Cerebral cortical gray expansion associated with two second-generation antipsychotics. Biol Psychiatry. 2005;58(1):62–66.CrossRefGoogle ScholarPubMed
Lieberman, JA, Tollefson, GD, Charles, C, et al. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry. 2005;62(4):361–370.CrossRefGoogle ScholarPubMed
Crespo-Facorro, B, Roiz-Santianez, R, Perez-Iglesias, R, et al. Effect of antipsychotic drugs on brain morphometry. A randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(8):1936–1943.CrossRefGoogle ScholarPubMed
Fusar-Poli, P, Smieskova, R, Kempton, MJ, Ho, BC, Andreasen, NC, Borgwardt, S. Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies. Neurosci Biobehav Rev. 2013;37(8):1680–1691.CrossRefGoogle ScholarPubMed
Navari, S, Dazzan, P. Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings. Psychol Med. 2009;39(11):1763–1777.CrossRefGoogle ScholarPubMed
Smieskova, R, Fusar-Poli, P, Allen, P, et al. The effects of antipsychotics on the brain: what have we learnt from structural imaging of schizophrenia?A systematic review. Curr Pharm Des. 2009;15(22):2535–2549.CrossRefGoogle ScholarPubMed
Torres, US, Portela-Oliveira, E, Borgwardt, S, Busatto, GF. Structural brain changes associated with antipsychotic treatment in schizophrenia as revealed by voxel-based morphometric MRI: an activation likelihood estimation meta-analysis. BMC Psychiatry. 2013;13(1):342CrossRefGoogle ScholarPubMed
Cahn, W, Hulshoff Pol, HE, Lems, EB, et al. Brain volume changes in first-episode schizophrenia: a 1-year follow-up study. Arch Gen Psychiatry. 2002;59(11):1002–1010.CrossRefGoogle ScholarPubMed
Emsley, R, Asmal, L, du Plessis, S, Chiliza, B, Phahladira, L, Kilian, S. Brain volume changes over the first year of treatment in schizophrenia: relationships to antipsychotic treatment. Psychol Med. 2017;47(12):2187–2196.CrossRefGoogle ScholarPubMed
Lesh, TA, Tanase, C, Geib, BR, et al. A multimodal analysis of antipsychotic effects on brain structure and function in first-episode schizophrenia. JAMA Psychiatry. 2015;72(3):226–234.CrossRefGoogle ScholarPubMed
Rosenberg, WM, Deeks, J, Lusher, A, Snowball, R, Dooley, G, Sackett, D. Improving searching skills and evidence retrieval. J R Coll Physicians Lond. 1998;32(6):557–563.Google ScholarPubMed
Richardson, WS, Wilson, MC, Nishikawa, J, Hayward, RS. The well-built clinical question: a key to evidence-based decisions. ACP J Club. 1995;123(3):A12–A13.CrossRefGoogle ScholarPubMed
Dawes, M, Summerskill, W, Glasziou, P, et al. Sicily statement on evidence-based practice. BMC Med Educ. 2005;5(1):1CrossRefGoogle ScholarPubMed
Evidence-Based Medicine Working Group. Evidence-based medicine. A new approach to teaching the practice of medicine. JAMA. 1992;268(17):2420–2425.CrossRefGoogle Scholar
Rosenberg, W, Donald, A. Evidence based medicine: an approach to clinical problem-solving. BMJ. 1995;310(6987):1122–1126.CrossRefGoogle ScholarPubMed
Correll, CU, Robinson, DG, Schooler, NR, et al. Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study. JAMA Psychiatry. 2014;71(12):1350–1363.CrossRefGoogle ScholarPubMed
De Hert, M, Detraux, J. The urgent need for optimal monitoring of metabolic adverse effects in children and youngsters who take on-label or off-label antipsychotic medication. JAMA Psychiatry. 2018;75(8):771–772.CrossRefGoogle ScholarPubMed
Lee, EHM, Hui, CLM, Law, EYL, et al. Metabolic screening for patients with second-generation antipsychotic medication: a population-based study from 2004 to 2016. Schizophr Res. 2018;197:618–619.CrossRefGoogle ScholarPubMed
Kasper, S, Lowry, AJ, Hodge, A, Bitter, I, Dossenbach, M. Tardive dyskinesia: analysis of outpatients with schizophrenia from Africa and the Middle East, Asia, Central and Eastern Europe, and Latin America. Schizophr Res. 2006;81(2–3):139–143.CrossRefGoogle ScholarPubMed
Takeuchi, H, Suzuki, T, Uchida, H, Watanabe, K, Mimura, M. Antipsychotic treatment for schizophrenia in the maintenance phase: a systematic review of the guidelines and algorithms. Schizophr Res. 2012;134(2–3):219–225.CrossRefGoogle ScholarPubMed
Alvarez-Jimenez, M, O'Donoghue, B, Thompson, A, et al. Beyond clinical remission in first episode psychosis: thoughts on antipsychotic maintenance vs. guided discontinuation in the functional recovery era. CNS Drugs. 2016;30(5):357–368.CrossRefGoogle ScholarPubMed
McGorry, P, Alvarez-Jimenez, M, Killackey, E. Antipsychotic medication during the critical period following remission from first-episode psychosis: less is more. JAMA Psychiatry. 2013;70(9):898–900.CrossRefGoogle ScholarPubMed
Emsley, R. On discontinuing treatment in schizophrenia: a clinical conundrum. NPJ Schizophr. 2017;3:4CrossRefGoogle ScholarPubMed
McNeil, TF, Kaij, L. Obstetric complications and physical size of offspring of schizophrenic, schizophrenic-like, and control mothers. Br J Psychiatry. 1973;123(574):341–348.CrossRefGoogle ScholarPubMed
Lewis, SW, Mezey, GC. Clinical correlates of septum pellucidum cavities: an unusual association with psychosis. Psychol Med. 1985;15(1):43–54.CrossRefGoogle ScholarPubMed
Murray, RM, Lewis, SW. Is schizophrenia a neurodevelopmental disorder? Br Med J (Clin Res Ed). 1987;295(6600):681–682.CrossRefGoogle ScholarPubMed
Jones, P. Child developmental risk factors for adult schizophrenia in the British 1946 birth cohort. Lancet. 1994;344(8934):1398–1402.CrossRefGoogle ScholarPubMed
O'Callaghan, E, Sham, P, Takei, N, Glover, G, Murray, RM. Schizophrenia after prenatal exposure to 1957 A2 influenza epidemic. Lancet. 1991;337(8752):1248–1250.CrossRefGoogle ScholarPubMed
Wright, P, Laing, P, Donaldson, PT, Murray, RM. Schizophrenia: the teratogenic antibody hypothesis. In: Müller, N, ed. Psychiatry, Psychoimmunology, and Viruses. Vienna, Austria: Springer; 1999:89–99.CrossRefGoogle Scholar
Murray, RM, O'Callaghan, E, Castle, DJ, Lewis, SW. A neurodevelopmental approach to the classification of schizophrenia. Schizophr Bull. 1992;18(2):319–332.CrossRefGoogle ScholarPubMed
Jones, P, Murray, RM. The genetics of schizophrenia is the genetics of neurodevelopment. Br J Psychiatry. 1991;158:615–623.CrossRefGoogle ScholarPubMed
Howes, OD, Murray, RM. Schizophrenia: an integrated sociodevelopmental-cognitive model. Lancet. 2014;383(9929):1677–1687.CrossRefGoogle ScholarPubMed
Birley, JL, Brown, GW. Crises and life changes preceding the onset or relapse of acute schizophrenia: clinical aspects. Br J Psychiatry. 1970;116(532):327–333.CrossRefGoogle ScholarPubMed
Howes, OD, McCutcheon, R, Owen, MJ, Murray, RM. The role of genes, stress, and dopamine in the development of schizophrenia. Biol Psychiatry. 2017;81(1):9–20.CrossRefGoogle ScholarPubMed
Shorter, E. A History of Psychiatry: From the Era of the Asylum to the Age of Prozac. John Wiley & Sons; 1997.Google Scholar